Table 1.
Demographic, clinical, and pathological data of patients included in this study
| n (23) | % | |
|---|---|---|
| Age at diagnosis | ||
| Median (range) | 63 (46–82) | – |
| Sex | ||
| Female | 14 | 61% |
| Male | 9 | 39% |
| Tumor location | ||
| Pancreas | 7 | 30% |
| Small bowel | 5 | 22% |
| Stomach | 2 | 9% |
| Colon | 2 | 9% |
| Lung | 1 | 4% |
| Suprarenal | 1 | 4% |
| Bladder | 1 | 4% |
| Unknown | 4 | 17% |
| Type of sample | ||
| Primary tumor excision | 9 | 39% |
| Biopsy from metastasis | 14 | 61% |
| Site of metastasis | ||
| Liver | 15 | 65% |
| Other | 8 | 35% |
| Proliferation indexa Ki-67 ≥ 5% | 13 | 57% |
| Positive octreoscan scintigraphy | 18 | 78% |
| Carcinoid syndrome | 5 | 22% |
| Therapeutics | ||
| Somatostatin analogs (SSAs) | 7 | 30% |
| SSAs + chemotherapy | 6 | 26% |
| SSAs + IFN | 4 | 17% |
| SSAs + chemotherapy + IFN | 6 | 26% |
Note:
a
Proliferation index was measured by Ki-67 immunohistochemistry according to standard protocols in the Department of Pathology, HSM, Hospital de Santa Maria.